MET and hepatocellular carcinoma: Currently, there are only limited studies on the efficacy of second generation mTOR inhibitors for HCC treatment.48 Importantly, the sgPten/c-Met murine HCC model shows high levels of mTORC1 and mTORC2 activities, and our investigation demonstrates its dependence by mTORC2.